Hefei Lifeon Pharmaceutical Co., Ltd. (SHE:003020)
China · Delayed Price · Currency is CNY 17.39
+0.46 (2.72%)
Aug 4, 2026, 3:04 PM CST
SHE:003020 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 3,969 | 4,922 | 3,456 | 4,495 | 3,956 | 4,248 | |
Market Cap Growth | -22.42% | 42.42% | -23.11% | 13.63% | -6.89% | 33.39% |
Enterprise Value | 3,699 | 4,651 | 3,230 | 4,180 | 3,310 | 3,631 |
Last Close Price | 17.39 | 21.24 | 14.36 | 18.32 | 16.01 | 17.19 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.25 | 29.80 | 21.52 | 19.83 | 18.90 | 24.67 |
Forward PE | - | 24.47 | 15.83 | 17.14 | 14.90 | - |
PS Ratio | 2.56 | 3.17 | 2.28 | 2.37 | 1.53 | 1.87 |
PB Ratio | 2.00 | 2.52 | 1.81 | 2.40 | 2.67 | 3.26 |
P/TBV Ratio | 2.37 | 3.01 | 2.22 | 3.00 | 2.83 | 3.50 |
P/FCF Ratio | 31.25 | 52.12 | 80.29 | 732.38 | - | - |
P/OCF Ratio | 16.50 | 23.12 | 17.50 | 22.07 | 19.72 | 26.77 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.39 | 2.99 | 2.13 | 2.20 | 1.28 | 1.60 |
EV/EBITDA Ratio | 16.48 | 21.28 | 14.19 | 17.31 | 14.99 | 18.17 |
EV/EBIT Ratio | 27.89 | 34.53 | 21.22 | 20.31 | 16.99 | 21.07 |
EV/FCF Ratio | 29.13 | 49.26 | 75.04 | 681.13 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.06 | 0.06 | 0.05 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 0.33 | 0.51 | 0.50 | 0.35 | 0.06 | 0.12 |
Debt / FCF Ratio | 0.58 | 1.21 | 2.76 | 14.41 | - | - |
Net Debt / Equity Ratio | -0.21 | -0.17 | -0.20 | -0.25 | -0.42 | -0.48 |
Net Debt / EBITDA Ratio | -1.89 | -1.56 | -1.71 | -1.97 | -2.85 | -3.15 |
Net Debt / FCF Ratio | -3.25 | -3.60 | -9.05 | -77.56 | 13.74 | 22.30 |
Asset Turnover | 0.59 | 0.60 | 0.60 | 0.83 | 1.36 | 1.42 |
Inventory Turnover | 2.39 | 2.65 | 2.07 | 3.08 | 5.88 | 7.16 |
Quick Ratio | 1.81 | 1.82 | 1.60 | 1.62 | 1.61 | 2.98 |
Current Ratio | 2.28 | 2.26 | 2.04 | 2.12 | 2.33 | 3.72 |
Return on Equity (ROE) | 8.10% | 8.46% | 8.05% | 13.95% | 15.03% | 13.90% |
Return on Assets (ROA) | 3.16% | 3.26% | 3.75% | 5.59% | 6.41% | 6.71% |
Return on Invested Capital (ROIC) | 7.42% | 7.73% | 9.25% | 16.64% | 22.29% | 28.18% |
Return on Capital Employed (ROCE) | 6.30% | 6.50% | 7.60% | 10.60% | 13.00% | 12.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.09% | 3.36% | 4.65% | 5.04% | 5.29% | 4.05% |
FCF Yield | 3.20% | 1.92% | 1.25% | 0.14% | -1.16% | -0.66% |
Dividend Yield | 2.46% | 1.96% | 2.90% | 1.90% | 1.67% | 1.67% |
Payout Ratio | 79.09% | 100.59% | 50.40% | 27.03% | 30.99% | 26.90% |
Buyback Yield / Dilution | 1.57% | 0.68% | 0.48% | -1.75% | -0.49% | -33.02% |
Total Shareholder Return | 4.04% | 2.65% | 3.38% | 0.14% | 1.18% | -31.35% |